Hold control (command on a Mac) and press the + key as many times as necessary to increase the font size.
Hold control (command on a Mac) and press the - key to reduce the font size. - hide

Top Line Teprotumumab Phase III Trial Results Released



Posted 5 months, 3 weeks ago (0 comments)

Horizon Pharma has just released top line results for the Phase III trial of Teprotumumab, a potential new treatment for thyroid eye disease. Detailed Phase III data will be submitted for publication in a peer-reviewed journal and presented at a medical congress later this year. Click this link to learn more: http://bit.ly/2ECfINj

Raymond Douglas, M.D., Ph.D., the study’s co-principal investigator, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, and a member of the GDATF's Physician Advisory Board stated: “In the study, patients treated with teprotumumab had an unprecedented reduction in proptosis [eye bulging], which is currently only treatable via surgery after the active disease has ended. If approved, teprotumumab would give physicians the first medicine shown to reduce proptosis during active thyroid eye disease, in addition to treating other painful symptoms.”

Comments

  • There are currently no comments

You must log in to comment.

Questions? Problems? Please contact us at [email protected] or 877-643-3123.

GDATF on Facebook

Support the GDATF and become a member today!

© 2019 Graves' Disease & Thyroid Foundation